FDA Fast Track for YUTREPIA in SSc-Raynaud's; Phase 2a RE-WARM Study to Start Q4
LQDA has more than doubled off its 52-week low of $21.145.
Summary
Liquidia announced FDA Fast Track designation for YUTREPIA in SSc-Raynaud's, a condition with no approved therapy, and plans to start the RE-WARM Phase 2a study in Q4 2026.
Key Events · Product Development and Regulatory · LQDA
-
FDA Fast Track for SSc-RP
FDA granted Fast Track designation to YUTREPIA for Raynaud's phenomenon associated with systemic sclerosis, a condition with no approved therapy affecting up to 90% of SSc patients.
-
RE-WARM Phase 2a Study
Liquidia plans to initiate RE-WARM (NCT07748000), a ~75-patient dose-finding study at up to 30 U.S. sites, in October 2026 with primary completion targeted for February 2027.
-
Addressable Market
Liquidia estimates ~30,000 U.S. patients with moderate to severe SSc-RP, representing a meaningful expansion opportunity beyond YUTREPIA's approved PAH and PH-ILD indications.
-
Regulatory Benefits
Fast Track enables more frequent FDA interactions, potential rolling NDA review, and possible Priority Review or Accelerated Approval if criteria are met.
Analysis · LQDA · Life Sciences
The FDA's Fast Track designation for YUTREPIA in systemic sclerosis-associated Raynaud's phenomenon (SSc-RP) validates a new indication with no approved therapy and a ~30,000-patient U.S. opportunity. The designation enables more frequent FDA interactions, rolling NDA review, and potential Priority Review or Accelerated Approval. Liquidia plans to initiate the RE-WARM Phase 2a dose-finding study in October 2026 with primary completion targeted for February 2027. This expands YUTREPIA's commercial runway beyond its approved PAH and PH-ILD indications, though the indication remains unapproved and clinical success is not guaranteed.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $70.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $21.15 to $93.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.